Geron Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GERN | KROS | SLDB | RIGL | SNDX | ZVRA | |
|---|---|---|---|---|---|---|
| Market cap | 693.87M | 214.73M | 699.11M | 958.09M | 940.80M | 663.32M |
| P/E (TTM) | — | — | — | 3.0 | — | 9.2 |
| Forward P/E | 27.0 | -1.6 | -3.8 | 10.4 | -14.4 | 10.4 |
| Price/book | 3.1 | 0.8 | 2.9 | 2.2 | -54.7 | 4.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −14.68% | −30.80% | +59.80% | +29.09% | −5.36% | +1.89% |
| Today | +16.13% | 0.00% | +3.82% | +4.97% | −26.87% | +8.87% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All GERN news ›Reviewing Geron (NASDAQ:GERN) and MDxHealth (NASDAQ:MDXH)
Posted by Mitch Edgeman on Nov 3rd, 2026 Geron (NASDAQ:GERN – Get Free Report) and MDxHealth (NASDAQ:MDXH – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses…
Geron: Opportunity Builds Even As Struggles Continue
Geron achieved FDA approval for RYTELO in June 2024, targeting lower-risk myelodysplastic syndromes. Read what makes GERN stock a compelling Buy. - Geron achieved FDA approval for RYTELO (imetelstat) in June 2024, targeting lower-risk…
Flashback: What the Enron Scandal Revealed About Financial Regulation in the ‘90s
It's been nearly 25 years since Enron's collapse. The cozy collaboration between Enron and its accounting firm was far from an anomaly at the time, the 2002 documentary ‘Bigger Than Enron’ reported. It’s now streaming on YouTube for the…
Did CVS Health Corporation Insiders Breach their Fiduciary Duties to Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of CVS Health Corporation (NYSE: CVS)... Shareholders are encouraged to contact the firm to discuss their rights and…
More from 1 other outlet
What Really Went Wrong with Enron?
I am going to concentrate on the third kind of explanation for what went wrong with Enron-the systemic explanations…. Second, a private company like Enron currently hires and pays its own auditors. This again is a conflict of interest…
Geron Corporation: IMPACT-MF Study Discontinuation May Not Be So Disastrous
With the MF label expansion closed, Geron Corporation will focus on maximizing Rytelo's approved lower-risk MDS indication. I rate the GERN stock as Hold. Click to know more. - Geron Corporation maintains a 'Hold' rating after…
Geron Halts Phase 3 Imetelstat Trial in Relapsed/Refractory Myelofibrosis
The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall survival. Primary myelofibrosis cells in blood flow: © LASZLO - stock.adobe.com Geron Corporation has discontinued the…
Geron drops after discontinuing late-stage trial for Rytelo
Geron (GERN) stock falls as the company halts a late-stage trial for its blood cancer therapy imetelstat, marketed as Rytelo. Read more here. Geron Corporation (GERN) lost more than 20% on Wednesday after the cancer drugmaker announced…
Geron discontinues late-stage trial of blood cancer drug
Oct 28 (Reuters) – Geron said on Wednesday it would discontinue a late-stage trial testing its treatment for patients with a form of rare blood cancer. The drug, branded as Rytelo, was being evaluated as a treatment for…
Contrasting Absci (NASDAQ:ABSI) & Geron (NASDAQ:GERN)
Posted by Defense World Staff on Oct 25th, 2026 Absci (NASDAQ:ABSI – Get Free Report) and Geron (NASDAQ:GERN – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- prnewswire.com14
- tradingview.com5
- markets.businessinsider.com4
- seekingalpha.com3
- globenewswire.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 41 articles, not a forecast.